GRM5 refers to the metabotropic glutamate receptor 5 (mGluR5), targeted by the drug ADX-48621, which is currently being investigated for Parkinson’s disease, dyskinesia, and mood disorders (https://clinicaltrials.gov/, NCT04857359). This evidence concerns the gene GRM5 and mood disorder.